Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- 12 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Oct 2019.
- 19 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2019.
- 15 Dec 2016 Status changed from recruiting to active, no longer recruiting.